Skip to main content
Tech.euFundingExplorerBeta

Xinvento

Exited

Xinvento aims to alleviate the difficulties associated with Congenital Hyperinsulinism (CHI) by developing an effective treatment to overcome the current difficulties of limited effective treatment options available to patients.

Amsterdam, Netherlandsxinvento.com ↗
Healthtech
← All companies
Total raised
€0
€0
Funding rounds
1
Investors
8
distinct backers
Active since
2022-04
latest 2022-04

Funding by year

EUR raised per year

Funding rounds

1 rounds
DateStageAmountInvestors
2022-04-26Seed—Daniel de Boer,David Meeker,Dinko Valerio,Ed Kaye,Hans Schikan,James Shannon+2 moreView deal →

Exit

Type
acquisition
Date
Mar 2023
Value
—
Acquiror
Rhythm Pharmaceuticals (Netherlands)

Investors

8
Daniel de BoerDavid MeekerDinko ValerioEd KayeHans SchikanJames ShannonJohn MaraganoreOnno van de Stolpe

Related news

Similar companies

same sector or country